CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Stimunity focuses on developing innovative biological drugs to enhance the immune response against tumors. Their lead product, STI-001, utilizes advanced virus-like particle technology to activate the STING pathway, aiming to improve treatment outcomes for cancer patients who are unresponsive to existing therapies.
Stimunity is a company that develops disruptive immuno-stimulatory biological drugs to restore the immune system against tumor cells.Immune checkpoint inhibitors showed great potential in cancer immunotherapy after achieving 5-year survival rates for patients with advanced or metastatic cancers, unseen by physicians before.
This is a promising beginning.
Nevertheless, 5 million patients worldwide remain unresponsive to immunotherapy and do not have any other therapeutic option.
On average it rep…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
